All the news Showing 4 of 34 articles from: Non-nucleoside Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis Keith Alcorn / 20 November 2012 The first major data on interferon-free hepatitis C treatment in people with cirrhosis show that treatment using BI-201335 – now known as faldaprevir – and BI-207127 with ribavirin can be safe, and proved ... 94% response rate to HCV treatment without ribavirin or interferon in harder-to-treat Keith Alcorn / 13 November 2012 Twelve weeks of treatment with a three-drug combination of new directly acting antivirals that contained neither pegylated interferon nor ribavirin led to a sustained virologic response 12 weeks after completion of treatment (SVR12) ... Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C Keith Alcorn / 12 November 2012 Over 79% of previously untreated and null responder patients with genotype 1a hepatitis infection achieved a sustained virologic response twelve weeks after completing treatment (SVR12) with an interferon-free combination of two or three ... Abbott interferon-free HCV combinations show early promise in untreated patients Caspar Thomson / 23 April 2012 Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naïve patients presented last week at the International Liver Congress in Barcelona. Abbott is pursuing the ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive